HIV vaccine MVA-BN starts Clinical Phase I/II Trial

It’s interesting to know that a lot of efforts are being put on the development of effective vaccine that will finally eradicate HIV/AIDS in the world. Despite of all this, it shows that we are way too far from reaching the point of success. Victory may be distant but shortcut is just around the corner!

Bavarian Nordic AS, one of the leading Europe-based pharmaceutical companies, is on its Clinical Phase I/II of its HIV vaccine. It is also developing effective vaccine against smallpox and other cancer including breast and prostate cancer.

The pharmaceutical company will provide feedback about the outcome of the research study by the second half of next year. The vaccine MVA-BN polytope is expected to provide protection against common or all types of HIV strains which exhibits common surface structure (protein coat).

For information regarding drugs and other vaccines developed by Bavarian Nordic AS, please visit the site.